



FY12 1st Quarter IRB Submission Report

Compiled by Cindy McConaughy-Smith
Research Integrity Office

Date: 10/20/2011

IRQ Submissions FY12 YTD

Federal 54


Foundation 13

Industry 28

Internal 140


Total 235

- YTD 20 studies have modified /updated existing funding
- 0 of the 140 unfunded studies have added funding



Top 5 Department IRQ Submissions FY12 YTD


Hematology	9
Surgery	27
Pediatric	15
Neurology	17
Casey Eye	13
Other*	154
Total	235



- *Remaining 46 (other) departments
- 25% of the top five submitting department protocols required oncology review
- 163% of all IRQ submissions YTD required oncology review

IRQ Review Categories FY12 YTD

Anticipated Human Research	1
Exempt	26
Expedited	97
Full Board	55
Non-Human Subjects Research	7
Waived	4



Key:

Anticipated Human Subjects : (1) Definite plans for involvement of human subjects are not available at the time of funding; and /or (2) Awards that support multiple projects, each of which will obtain its own IRB approval.


Exempt: Protocols meeting the federal regulations for this level of IRB Review.

Expedited : Protocols involving no more than minimal risk.

Full Board: Protocols that require review by the convened OHSU IRB .

Non Human Subjects: Protocols not meeting the federal definition of "human subjects research."

Waived: Protocols where OHSU's IRB agrees to waive oversight to another IRB



CRQ Submissions FY12 YTD


Federal 211

Foundation 46

Industry 82


Internal 228

Total 567



Modification Submissions FY12 YTD

Federal	405
Foundation	87
Industry	339
Internal	235
Total	1066



Unanticipated Event Submissions FY12 YTD

Federal	1
Foundation	0
Industry	14
Internal	1
Total	6

